SCHEMBL6630883

SCHEMBL6630883

CCOC(=O)C1CCc2ccc(NC=O)cc2O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.56
CYP4A11 Q02928 1/20 0.56
POLB P06746 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22070528 0.84 CYP4F2 (0.64) CYP4F2CYP4A11POLBKMT2AALDH1A1
SCHEMBL22070545 0.82 CYP4F2 (0.59) CYP4F2CYP4A11POLBNPC1RAB9A
SCHEMBL12660944 0.82 CYP4F2 (0.64) CYP4F2CYP4A11POLBNPC1RAB9A
SCHEMBL9837746 0.81 CYP4F2 (0.62) CYP4F2CYP4A11DRD2DRD1DRD4
SCHEMBL1019684 0.81 CYP4F2 (0.62) CYP4F2CYP4A11DRD2DRD1DRD4
SCHEMBL9838425 0.81 CYP4F2 (0.62) CYP4F2CYP4A11DRD2DRD1DRD4
SCHEMBL29586758 0.81 CYP4F2 (0.62) CYP4F2CYP4A11DRD2DRD1DRD4
SCHEMBL20730230 0.80 CYP4F2 (0.68) CYP4F2CYP4A11POLBNPC1KMT2A
SCHEMBL1020122 0.80 CYP4F2 (0.61) CYP4F2CYP4A11POLBNFKB1NFKB2
SCHEMBL1044067 0.80 CYP4F2 (0.61) CYP4F2CYP4A11POLBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432696-A1 CHROMAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2004-06-30 EP disclosed
US-6706757-B2 TREATING CENTRAL NERVOUS SYSTEM DISORDERS, CAUSED BY 5-HT6 RECEPTOR WYETH 2004-03-16 US disclosed
US-20030158175-A1 Chroman derivatives as 5-hydroxytrytamine-6 ligands WYETH 2003-08-21 US disclosed
WO-2003029238-A1 CHROMAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158175-A1 Chroman derivatives as 5-hydroxytrytamine-6 ligands HTR6, HTR1A, HTR1F CYP4F2 496/4885CYP4A11 573/4885POLB 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.